Homocystinuria: Reduced folate levels during pyridoxine treatment
Bridget Wilcken, Benjamin C. Turner
Abstract
Open-access reader
Bridget Wilcken, Benjamin C. Turner
Abstract
Open-access reader
Nine patients with homocystinuria due to cystathionine synthase deficiency were treated with pyridoxine: 6 responded biochemically and 5 of these showed marked clinical improvement. Full biochemical response was only obtained slowly in some patients. Response occurred in those patients who were least severely affected by their disease and was consistent within families. No patient experienced a thrombotic episode during pyridoxine treatment. Pretreatment serum and red cell folate levels were normal. All patients showed lowering of folate levels while receiving pyridoxine, and administration of folic acid caused further biochemical improvement in pyridoxine responsive patients and subjective clinical improvement in all. The mechanism for lowering of folate levels during pyridoxine administration may depend upon removal of substrate inhibition of the enzyme N5 methyltetrahydrofolate homocysteine methyl transferase, due to pyridoxine-induced lowering of the substrate homocysteine. It is suggested that patients with homocystinuria should be given a long trial with pyridoxine and that folic acid should be given in all cases where pyridoxine is used.
OpenAlex reports 40 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Nine patients with homocystinuria due to cystathionine synthase deficiency were treated with pyridoxine: 6 responded biochemically and 5 of these showed marked clinical improvement. Full biochemical response was only obtained slowly in some patients. Response occurred in those patients who were least severely affected by their disease and was consistent within families. No patient experienced a thrombotic episode during pyridoxine treatment. Pretreatment serum and red cell folate levels were normal. All patients showed lowering of folate levels while receiving pyridoxine, and administration of folic acid caused further biochemical improvement in pyridoxine responsive patients and subjective clinical improvement in all. The mechanism for lowering of folate levels during pyridoxine administration may depend upon removal of substrate inhibition of the enzyme N5 methyltetrahydrofolate homocysteine methyl transferase, due to pyridoxine-induced lowering of the substrate homocysteine. It is suggested that patients with homocystinuria should be given a long trial with pyridoxine and that folic acid should be given in all cases where pyridoxine is used.
Key concepts: Pyridoxine, Homocystinuria, Medicine, Homocysteine, Internal medicine, Cystathionine beta synthase, Endocrinology, Enzyme